H. Stewart Parker Joins Impel NeuroPharma's Board of Directors

H. Stewart Parker Joins Impel NeuroPharma's Board of Directors

Impel NeuroPharma is pleased to announce that H. Stewart Parker, a prominent leader in Seattle's Biotechnology community, has joined Impel's Board of Directors.

Most recently, Parker was the CEO of the Seattle-based Infection Disease Research Institute (IDRI), a nonprofit global health research institute developing diagnostics, vaccines, and treatments for neglected diseases. Parker started her career in biotech as the first employee of Immunex, growing with the company to become Vice President of Corporate Development.
 

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.